Pei-Shan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pei-Shan Wu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Miao-Hsia Lin
Department of Microbiology, National Taiwan University College of Medicine, Taipei, 100, Taiwan
4 shared publications - Bih-Show Lou
Chemistry Division, Center for General Education, Chang Gung University, Taoyuan, 333, Taiwan
2 shared publications Chun-Wei Hou
2 shared publications- Jyh-Wei Lee
Center for Plasma and Thin Film Technologies, Ming Chi University of Technology, New Taipei City 243303, Taiwan
2 shared publications Ting-An Chen
Department of Microbiology, National Taiwan University College of Medicine, Taipei, 100, Taiwan
2 shared publications- Andrew Yueh
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No.35, Keyan Road, Zhunan Town, Miaoli, 35053, Taiwan, ROC
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Elsevier in Journal of Materials Research and Technology
- Vol. 39, 47-58
Amorphous TiZrNbTaFe high entropy alloy coatings for enhanced osseointegration of orthopedic implants
- 12 September 2025
- Published by Elsevier in Journal of Materials Research and Technology
- Vol. 39, 47-58
Open AccessAmorphous TiZrNbTaFe high entropy alloy coatings for enhanced osseointegration of orthopedic implants
- Open Access
- 24 June 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (8) , 101019
A Methanolic Urea-Enhanced Protein Extraction Enabling the Largest Bacterial Phosphorylation Resource
- 24 June 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (8) , 101019
Open AccessA Methanolic Urea-Enhanced Protein Extraction Enabling the Largest Bacterial Phosphorylation Resource
- Open Access
- 6 April 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (5) , 100962
Cold Atmospheric Plasma Jet Promotes Wound Healing Through CK2-Coordinated PI3K/AKT and MAPK Signaling Pathways
- 6 April 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (5) , 100962
Open AccessCold Atmospheric Plasma Jet Promotes Wound Healing Through CK2-Coordinated PI3K/AKT and MAPK Signaling Pathways
- Open Access
- 15 April 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (5) , 100768
Quantification Quality Control Emerges as a Crucial Factor to Enhance Single-Cell Proteomics Data Analysis
- 15 April 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (5) , 100768
Open AccessQuantification Quality Control Emerges as a Crucial Factor to Enhance Single-Cell Proteomics Data Analysis
- 29 November 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1124-1133.e7
Delayed Collagen Production without Myofibroblast Formation Contributes to Reduced Scarring in Adult Skin Microwounds
- 29 November 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 1124-1133.e7
Delayed Collagen Production without Myofibroblast Formation Contributes to Reduced Scarring in Adult Skin Microwounds
- 1 June 2020
- Published by Elsevier in Chinese Chemical Letters
- Vol. 31 (6) , 1564-1567
Et2Zn-promoted β-trans-selective hydroboration of ynamide
- 1 June 2020
- Published by Elsevier in Chinese Chemical Letters
- Vol. 31 (6) , 1564-1567
Et2Zn-promoted β-trans-selective hydroboration of ynamide
- Open Access
- 1 January 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (1) , 44-53
Resistance Analysis and Characterization of a Thiazole Analogue, BP008, as a Potent Hepatitis C Virus NS5A Inhibitor
Hepatitis C virus (HCV) is a global health problem, affecting approximately 3% of the world's population. The standard treatment for HCV infection is often poorly tolerated and ineffective. Therefore, the development of novel or more effective treatment strategies to treat chronic HCV infection is urgently needed. In this report, BP008, a potent small-molecule inhibitor of HCV replication, was developed from a class of compounds with thiazol core structures by means of utilizing a cell-based HCV replicon system. The compound reduced the reporter expression of the HCV1b replicon with a 50% effective concentration (EC50) and selective index value of 4.1 ± 0.7 nM and >12,195, respectively. Sequencing analyses of several individual clones derived from BP008-resistant RNAs purified from cells harboring HCV1b replicon revealed that amino acid substitutions mainly within the N-terminal region (domain I) of NS5A were associated with decreased inhibitor susceptibility. Q24L, P58S, and Y93H are the key substitutions for resistance selection; F149L and V153M play the compensatory role in the replication and drug resistance processes. Moreover, BP008 displayed synergistic effects with alpha interferon (IFN-α), NS3 protease inhibitor, and NS5B polymerase inhibitor, as well as good oral bioavailability in SD rats and favorable exposure in rat liver. In summary, our results pointed to an effective small-molecule inhibitor, BP008, that potentially targets HCV NS5A. BP008 can be considered a part of a more effective therapeutic strategy for HCV in the future.
- 1 January 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (1) , 44-53
Open AccessResistance Analysis and Characterization of a Thiazole Analogue, BP008, as a Potent Hepatitis C Virus NS5A Inhibitor
Hepatitis C virus (HCV) is a global health problem, affecting approximately 3% of the world's population. The standard treatment for HCV infection is often poorly tolerated and ineffective. Therefore, the development of novel or more effective treatment strategies to treat chronic HCV infection is urgently needed. In this report, BP008, a potent small-molecule inhibitor of HCV replication, was developed from a class of compounds with thiazol core structures by means of utilizing a cell-based HCV replicon system. The compound reduced the reporter expression of the HCV1b replicon with a 50% effective concentration (EC50) and selective index value of 4.1 ± 0.7 nM and >12,195, respectively. Sequencing analyses of several individual clones derived from BP008-resistant RNAs purified from cells harboring HCV1b replicon revealed that amino acid substitutions mainly within the N-terminal region (domain I) of NS5A were associated with decreased inhibitor susceptibility. Q24L, P58S, and Y93H are the key substitutions for resistance selection; F149L and V153M play the compensatory role in the replication and drug resistance processes. Moreover, BP008 displayed synergistic effects with alpha interferon (IFN-α), NS3 protease inhibitor, and NS5B polymerase inhibitor, as well as good oral bioavailability in SD rats and favorable exposure in rat liver. In summary, our results pointed to an effective small-molecule inhibitor, BP008, that potentially targets HCV NS5A. BP008 can be considered a part of a more effective therapeutic strategy for HCV in the future.